Recurrent Astrocytoma, Recurrent Glioblastoma, Recurrent Glioma, Recurrent Oligodendroglioma
Conditions
Keywords
high grade gliomas
Brief summary
The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.
Detailed description
Patients will have tests and exams to see if they are eligible for the clinical trial. If found eligible, the patient will receive treatment with niraparib in the form of capsules taken every day for the first 28 days. If this dose is tolerated well, the patients will continue to take the capsules and more patients will be enrolled on the study. Patients will continue treatment with niraparib while on the study unless there is evidence of tumor growth or they experience unacceptable side effects. Patients will be monitored during treatment with tests and exams and after treatment completion for up to four years from the time they enrolled on the study.
Interventions
DRUGNiraparib
The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.
Sponsors
GlaxoSmithKline
University of Oklahoma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients must be able to understand and willing to sign the informed consent form. 2. Patients must be ≥ 18 years of age. 3. Patients must have histologically proven high-grade gliomas - GBM, Astrocytoma, or Oligodendroglioma (glioma WHO Grade III or IV) that is now recurrent by MRI or surgical pathology. 4. Patients must have measurable or evaluable lesions by RANO. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 6. Patient has archival tumor tissue available; or a fresh biopsy of recurrent or persistent tumor must be obtained for molecular assay by myChoice test (Myriad Genetics) prior to study treatment initiation. Patient will be requested to share reports from any prior genetic testing with the study investigators. 7. Participants have systolic BP\< 140 mmHg or diastolic BP \<90 mmHg that has been adequately treated or controlled. 8. Have adequate organ function defined per protocol. 9. Be able to take oral medications 10. Life expectancy ≥ 3 months, allowing adequate follow up of toxicity evaluation and antitumor activity. 11. Female patient, if of childbearing potential, has a negative serum pregnancy test within 72 hours of taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 180 days after the last dose of study treatment or is of nonchildbearing potential. 12. Male participant agrees to use an adequate method of contraception starting with the first dose of study treatment through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient. In addition, men must not donate sperm during niraparib therapy and for 90 days after receiving the last dose of niraparib. 13. Patient must agree to not breastfeed during the study or for 30 days after the last dose of study treatment. 14. Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment. 15. Participant receiving corticosteroids may continue as long as their dose is stable for at least 4 weeks prior to initiating protocol therapy.
Exclusion criteria
1. Patient has a known additional malignancy that progressed or required active treatment within the last 3 years (exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer). 2. Prior treatment with a known poly (ADP-ribose) polymerase (PARP) inhibitor 3. Participants with human immunodeficiency virus (HIV) with detectable viral load. Participants with HIV on effective anti-retroviral therapy with documented undetectable viral load and CD4 count ≥ 350 within 6 months of the first dose of study treatment are eligible for this trial. 4. Known active hepatitis B or hepatitis C. 5. Known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). 6. Participant is pregnant or expecting to conceive while receiving study treatment and/or for up to 180 days after the last dose of study treatment. Patient currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first dose of study drug. 7. Received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 4 weeks 8. Patients must not have a known hypersensitivity to the components of niraparib or the excipients (lactose monohydrate and magnesium stearate). 9. Patients must not have had major surgery within 4 weeks (including craniotomy) of starting the study and patient must have recovered from any effects of any major surgery. Stereotactic biopsy by burr hole is considered a minor surgery, and those patients undergoing this surgery will be eligible for the study 2 weeks post-procedure. 10. Patients must not have had radiotherapy encompassing \> 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy. 11. Patients must not have received a transfusion (platelets or red blood cells), colony stimulating factors (eg, granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) ≤ 4 weeks of the first dose of study treatment. 12. Patient has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted \> 4 weeks and was related to the most recent treatment. 13. Participants have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels. 14. Participants have received live vaccine within 30 days of planned start of study randomization. 15. Patients have medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent 16. Any medical condition not yet specified above that is considered to possibly, probably or definitely interfere with study procedures, including adequate follow-up and compliance and/or would jeopardize safe treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients Who Experience Adverse Events | Up to 17 months | Number of patients who experience adverse events with individualized starting dose (ISD) of niraparib using CTCAE v5.0 |
| Efficacy of Treatment in Dose Expansion Phase | up to 12 months | Percentage of patients who respond to niraparib monitored by disease control rate (stable disease and better) using RANO from start of treatment for up to 12 months. |
| Number of Patients Who Experience Toxicities With Individualized Starting Dose (ISD) of Niraparib Using CTCAE v5.0 | 5 months | Number of patients who experience toxicities (defined as grade 3 or 4 adverse events) with individualized starting dose (ISD) of niraparib using CTCAE v5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival in Dose Expansion Phase | 20 months | Proportion of patients who have progression-free survival from date of study entry until the first documented date of progression or date of death, whichever comes first. |
| Overall Survival in Dose Expansion Phase | 20 months | Proportion of patients with overall survival on the study defined as time from date of study entry to death by any cause. |
| Duration of Disease Control of All Patients | up to 4 years | Duration of response in patients treated with niraparib defined as time from date of first response (stable disease or better) to the first date of non-response post treatment on the study. |
Countries
United States
Participant flow
Recruitment details
This study was a multisite study, but only enrolled participants at University of Oklahoma Health Sciences Center Stephenson Cancer Center (OUHSC SCC). The study activated at SCC on 4/14/2022 and the last patient went off study on 2/6/2024. The first patient enrolled on 6/9/2022 and the last patient enrolled on 9/28/2023.
Pre-assignment details
Of the 15 enrolled participants, 9 met inclusion criteria and were evaluable.
Participants by arm
| Arm | Count |
|---|---|
| Niraparib Treatment Patients were treated with individualized starting dose of Niraparib.
Niraparib: The starting dose was 300 mg niraparib (or modified according to patient weight and platelet count), taken orally once a day for each cycle of 28 days. | 9 |
| Total | 9 |
Baseline characteristics
| Characteristic | Niraparib Treatment |
|---|---|
| Age, Continuous | 56.3 years STANDARD_DEVIATION 13.1 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Primary Site of Cancer Astrocytoma | 2 number of participants |
| Primary Site of Cancer GBM | 6 number of participants |
| Primary Site of Cancer Oligodendroglioma | 1 number of participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 6 Participants |
| Region of Enrollment United States | 9 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 6 / 9 |
| other Total, other adverse events | 9 / 9 |
| serious Total, serious adverse events | 1 / 9 |
Outcome results
Primary
Efficacy of Treatment in Dose Expansion Phase
Percentage of patients who respond to niraparib monitored by disease control rate (stable disease and better) using RANO from start of treatment for up to 12 months.
Time frame: up to 12 months
Population: study terminated early, only 6 participants in dose expansion phase.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Niraparib Treatment | Efficacy of Treatment in Dose Expansion Phase | 0 participants |
Primary
Number of Patients Who Experience Adverse Events
Number of patients who experience adverse events with individualized starting dose (ISD) of niraparib using CTCAE v5.0
Time frame: Up to 17 months
Population: All patients enrolled in study
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Niraparib Treatment | Number of Patients Who Experience Adverse Events | 9 Participants |
Primary
Number of Patients Who Experience Toxicities With Individualized Starting Dose (ISD) of Niraparib Using CTCAE v5.0
Number of patients who experience toxicities (defined as grade 3 or 4 adverse events) with individualized starting dose (ISD) of niraparib using CTCAE v5.0
Time frame: 5 months
Population: Patients who received at least one dose of Niraparib
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Niraparib Treatment | Number of Patients Who Experience Toxicities With Individualized Starting Dose (ISD) of Niraparib Using CTCAE v5.0 | 5 Participants |
Secondary
Duration of Disease Control of All Patients
Duration of response in patients treated with niraparib defined as time from date of first response (stable disease or better) to the first date of non-response post treatment on the study.
Time frame: up to 4 years
Population: Outcome measure was not calculated due to early study termination-- no patients experienced response to treatment. Due to this, we cannot calculate a duration of response because we don't have any responders to evaluate
Secondary
Overall Survival in Dose Expansion Phase
Proportion of patients with overall survival on the study defined as time from date of study entry to death by any cause.
Time frame: 20 months
Population: Patients who enrolled in study and consumed at least one dose of study drug. Patient must be in the dose expansion phase
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Niraparib Treatment | Overall Survival in Dose Expansion Phase | 10.81 Months |
Secondary
Progression Free Survival in Dose Expansion Phase
Proportion of patients who have progression-free survival from date of study entry until the first documented date of progression or date of death, whichever comes first.
Time frame: 20 months
Population: Patients who enrolled in study and took at least one dose of study drug. Patient must be in the dose expansion phase.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Niraparib Treatment | Progression Free Survival in Dose Expansion Phase | 1.62 Months |